Google’s parent company, Alphabet, is seeking regulatory approval to release up to 32 million mosquitoes across parts of the United States. The mosquitoes are specially treated in an experiment designed to reduce the spread of deadly mosquito-borne diseases, according to Euro Weekly News.

EPA reviewing proposal

The company’s “Debug” initiative is under review by the U.S. Environmental Protection Agency (EPA), and the plan would be to deploy millions of laboratory-reared insects in California and Florida over the next two years.

A public consultation period closed in early June 2026, and now regulators in the EPA will decide whether to approve, reject or modify the application. If it is approved, the programme, which uses only biological methods, will represent the biggest mosquito suppression trial in the United States.

How the programme works

Since only female mosquitoes bite, the project’s plan is to release only male mosquitoes, which cannot directly transmit disease. Male mosquitoes carry a naturally occurring bacterium known as Wolbachia, which interferes with reproduction when they mate with wild female mosquitoes, Euro Weekly News reports. This way, the eggs produced do not hatch, resulting in a gradually declining mosquito population.

Instead of radiation-induced sterility, the mosquitoes are rendered “reproductively incompatible” through Wolbachia infection, and the Debug programme illustrates a shift away from chemical insecticides towards biological methods for the control of animal populations.

Previous trials show results

Mosquitoes are widely regarded as some of the deadliest animals in the world due to their role in spreading infectious diseases. According to Euro Weekly News, mosquito-borne illnesses such as malaria, dengue fever and West Nile virus contribute to hundreds of thousands of deaths globally each year.

Among the target species is Aedes aegypti, which is known to transmit diseases including dengue fever, Zika virus, chikungunya and yellow fever.

Similar Wolbachia-based mosquito-control programmes have already been tested in countries such as Singapore and parts of the United States, with some trials reporting reductions of between 70 percent and 90 percent in targeted mosquito populations, alongside declines in disease transmission.